A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma

This study has been completed.

Sponsor:

Can-Fite BioPharma

ClinicalTrials.gov Identifier:

NCT00790218

First Posted: November 13, 2008

Last Update Posted: February 27, 2015

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Explanation of how the number of participants for analysis was determined.
Includes whether analysis was per protocol, intention to treat, or another method.
Also provides relevant details such as imputation technique, as appropriate.

No text entered.

Reporting Groups

Description

CF102

CF102: CF102 capsules twice daily by mouth

Baseline Measures

CF102

Overall Participants Analyzed [Units: Participants]

19

Age [Units: Participants]

<=18 years

0

Between 18 and 65 years

7

>=65 years

12

Gender [Units: Participants]

Female

7

Male

12

Region of Enrollment [Units: Participants]

Israel

19

Outcome Measures

1. Primary:

Dose Limiting Toxicity [ Time Frame: From start of treatment until Day 28 of Cycle 1 ]